The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correction to Roberts, N Engl J Med 359(4):420-422 July 24, 2008.

Correspondence
PreviousPrevious
Volume 359:2497-2499 December 4, 2008 Number 23
NextNext

Sorafenib in Advanced Hepatocellular Carcinoma

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Roberts, L. R.
-Related Article
by Llovet, J. M.
-PubMed Citation
To the Editor: Llovet et al. (July 24 issue)1 report that their study of sorafenib therapy in patients with hepatocellular carcinoma showed a higher overall incidence of treatment-related adverse events with sorafenib than with placebo (80% vs. 52%), although the difference was not noted to be significant. The availability of new therapies, with expected small variations in objective end points, has heightened awareness of the importance of the impact of treatment on patients' overall lives.2 Besides the traditional end points (e.g., median overall survival and time to radiologic progression), quality of life has been acknowledged as an important issue in . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.